<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0413066</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2830</journal-id>
<journal-id journal-id-type="nlm-ta">Cell</journal-id>
<journal-id journal-id-type="iso-abbrev">Cell</journal-id>
<journal-title-group>
<journal-title>Cell</journal-title>
</journal-title-group>
<issn pub-type="ppub">0092-8674</issn>
<issn pub-type="epub">1097-4172</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30340033</article-id>
<article-id pub-id-type="pmc">6461399</article-id>
<article-id pub-id-type="doi">10.1016/j.cell.2018.09.010</article-id>
<article-id pub-id-type="manuscript">NIHMS1509520</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Stem cells, genome editing and the path to translational medicine</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Soldner</surname>
<given-names>Frank</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jaenisch</surname>
<given-names>Rudolf</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>The Whitehead Institute, 455 Main Street, Cambridge, MA 02142, USA</aff>
<aff id="A2"><label>2</label>Department of Biology, Massachusetts Institute of Technology, 31 Ames Street, Cambridge, MA 02139, USA</aff>
<author-notes>
<corresp id="CR1"><label>3</label>Correspondence should be addressed to R.J. (<email>jaenisch@wi.mit.edu</email>)</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>31</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<day>18</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>18</day>
<month>10</month>
<year>2019</year>
</pub-date>
<volume>175</volume>
<issue>3</issue>
<fpage>615</fpage>
<lpage>632</lpage>
<!--elocation-id from pubmed: 10.1016/j.cell.2018.09.010-->
<abstract id="ABS1">
<title>Summary</title>
<p id="P1">The derivation of human embryonic stem cells (hESCs) and the stunning discovery that somatic cells can be reprogrammed into human induced pluripotent stem cells (hiPSCs) holds the promise to revolutionize biomedical research and regenerative medicine. In this review, we focus on disorders of the central nervous system and explore how advances in human pluripotent stem cells (hPSCs) coincide with evolutions in genome engineering and genomic technologies to provide realistic opportunities to tackle some of the most devastating complex disorders.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>